Uveal Melanoma
Research activity is centered on uveal melanoma, with studies addressing both early-stage eye cancer and metastatic disease. The sponsor’s programs include treatment strategies for HLA-A2 negative metastatic cases and disease control in primary ocular tumors.
- Primary uveal melanoma
- Metastatic uveal melanoma
- HLA-A2 negative disease
Key interests include preservation of vision, prevention of enucleation, and tumor control in ocular malignancies.
Ocular Oncology
The clinical portfolio includes interventions directed at eye tumors before local treatment, with emphasis on reducing tumor burden ahead of surgery or radiation therapy. This area reflects a focus on managing cancers of the eye wall and supporting organ-sparing care.
- Preoperative tumor shrinkage
- Vision preservation
- Eye salvage
Research in this field is closely tied to maintaining ocular function while controlling malignant growth.
Advanced Solid Tumors
Another active area is advanced solid tumors, where the sponsor evaluates targeted approaches for adults with refractory or progressing cancers. These studies extend the company’s oncology focus beyond ocular disease into broader solid tumor treatment.
- Advanced solid tumor malignancies
- Targeted cancer therapy
- Late-stage oncology
This domain includes interest in tumor biology and therapeutic options for difficult-to-treat solid cancers.
Precision Oncology and Targeted Pathways
The sponsor’s research also covers precision oncology with attention to molecularly defined cancer subsets and combination-based treatment strategies. Its work spans signal pathway inhibition and targeted approaches relevant to tumor growth and resistance mechanisms.
- Molecularly selected cancer populations
- Combination targeted therapy
- Tumor progression control
These studies reflect a therapeutic interest in matching treatment approaches to specific oncologic biology.
